Call for less regulation in German healthcare sector
This article was originally published in Clinica
Germany's industry federation, the BDI, has urged that market forces be allowed to have due influence over the national healthcare products sector. Speaking at the annual general meeting of medtech industry association Spectaris, in Stuttgart last week, BDI deputy-president Friedhelm Loh said: "German can only be a worldwide leader in healthcare innovations when there is free pricing that promotes competition for such innovative products." He added that only then will it be possible for companies to invest in relatively costly and high-risk products.
You may also be interested in...
In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.